Rhabdomyosarcoma and soft tissue sarcoma in childhood.
The past year has seen a greater understanding of the means by which the alveolar rhabdomyosarcoma gene fusions (PAX-FKHR) lead to the malignant phenotype. The treatment of the primary tumor in rhabdomyosarcoma has been reexamined, with the roles of surgery and radiation expanding in American studies and decreasing in European ones. "Megatherapy" approaches with stem cell or bone marrow autologous transplants still have not found a role in the treatment of metastatic rhabdomyosarcoma. Our understanding of the natural history of nonrhabdo soft tissue sarcomas in children has increased, and molecular diagnosis is becoming established. The role of chemotherapy in treatment remains controversial.
Womer
R B
RB
Department of Pediatrics, The Children's Hospital of Philadelphia and University of Pennsylvania, 19104, USA. rwomer@mail.med.upenn.edu
Pressey
J G
JG
D002648:Child; D002675:Child, Preschool; D006801:Humans; D012208:Rhabdomyosarcoma / Q000473:pathology* / Q000628:therapy; D012509:Sarcoma / Q000473:pathology* / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000473:pathology* / Q000628:therapy